a 2023

Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.

SLABÝ, Ondřej; Petra POKORNÁ; Hana PÁLOVÁ; Michal KÝR; Peter MÚDRY et. al.

Basic information

Original name

Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.

Authors

SLABÝ, Ondřej; Petra POKORNÁ; Hana PÁLOVÁ; Michal KÝR; Peter MÚDRY and Jaroslav ŠTĚRBA

Edition

2023 ASCO Annual Meeting I, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakta

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

Organization

Lékařská fakulta – Repository – Repository

ISSN

UT WoS

001053772002601

Keywords in English

high-risk/refractory pediatric solid tumors; genomic profiling; individual therapeutic planning

Links

LX22NPO5102, research and development project. NU20-03-00240, research and development project.
Changed: 15/11/2023 03:33, RNDr. Daniel Jakubík

Abstract

V originále

gt; 10 mut/Mb). Lymphomas and CNS tumors showed the highest rate of patients with therapeutically actionable findings (60% and 56%, respectively), followed by neuroblastomas (36%), sarcomas (25%), and other solid tumors (23%). All results and individual treatment plans were discussed and approved at multidisciplinary molecular tumor boards. Conclusions: Precision medicine in pediatric oncology has rapidly developed over the last decade and resulted in new therapeutic options based on molecular biomarkers and increased our understanding of the complexity of pediatric malignancies.